ArticleGeneral thoracic and cardiovascular surgery2025
Pretreatment platelet level is associated with tumor proliferation and prognosis in malignant pleural mesothelioma.
Article in General thoracic and cardiovascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe present study aimed to investigate the relationship between serum-based inflammatory biomarkers and MPM tumor biology and prognosis.
methodsA total of 83 patients with MPM who were diagnosed and started treatment between January 1998 and December 2010 were studied. Clinicopathological variables were evaluated, including age, sex, clinical stage, histology, surgical resection, and chemotherapy. The cut-off values for pretreatment levels of white blood cell count, neutrophil count, lymphocyte count, platelet count, C-reactive protein, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index were determined using receiver operating characteristic curve analysis for predicting 5-year survival. Univariate and multivariate Cox regression analyses were performed to estimate the prognostic impact on 5-year overall survival.
resultsThe mean Ki-67 proliferation index in MPM cells was 35.1 ± 29.5% and the median overall survival of patients was 15.0 months. The Ki-67 proliferation index in MPM cells was significantly higher in the platelet-high group compared with that in the platelet-low group (42.1 ± 31.9 vs. 27.7 ± 25.1%; P = 0.027). Multivariate Cox regression analyses identified platelet count (hazard ratio = 1.929; P = 0.022) and PLR (hazard ratio = 1.776; P = 0.040) as significant prognostic factors.
conclusionPretreatment platelet level may be a useful prognostic marker for 5-year overall survival related to tumor proliferation in patients with MPM.
Indexed as
Identifiers
40232673What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.